Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica
Colon Cancer
Initial criteria
- age ≥ 18 years
- EITHER microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) OR POLE/POLD1 mutation positive with ultrahypermutated phenotype (tumor mutation burden > 50 mutations/megabase)
- prescribed by or in consultation with an oncologist
Approval duration
1 year